Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Jovanovic

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Plos One|November 15, 2023
Transcultural adaptation and validation of the Serbian version of Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-Patient Satisfaction (FACIT-TS-PS) questionnaireIvana Radovic, Igor Krdzic, Ana Jovanovic, et al.
Molecular Genetics and Metabolism Reports|July 24, 2025
Iron metabolism and hematological abnormalities in adult patients affected with mucopolysaccharidosesGabija Kaciulyte, Goknur Yorulmaz, Reena Sharma, et al.
JIMD Reports|December 8, 2017
Haematopoietic Stem Cell Transplantation Arrests the Progression of Neurodegenerative Disease in Late-Onset Tay-Sachs DiseaseKarolina M Stepien, Su Han Lum, J Edmond Wraith, et al.
Nanoscale|May 11, 2023
Defect-free graphene enhances enzyme delivery to fibroblasts derived from patients with lysosomal storage disordersYingxian Chen, Tooba Taufiq, Niting Zeng, et al.
Orphanet Journal of Rare Diseases|January 7, 2022
Cardiac device implantation and device usage in Fabry and hypertrophic cardiomyopathyRavi Vijapurapu, William Bradlow, Francisco Leyva, et al.
JIMD Reports|May 17, 2017
Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry RegistryWilliam R Wilcox, Ulla Feldt-Rasmussen, Ana Maria Martins, et al.
Frontiers in Cardiovascular Medicine|December 25, 2023
Clinical utilisation of implantable loop recorders in adults with Fabry disease-a multi-centre snapshot studyAshwin Roy, Ravi Vijapurapu, Hibba Kurdi, et al.
Orphanet Journal of Rare Diseases|October 21, 2023
Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label studyAleš Linhart, Gabriela Dostálová, Kathy Nicholls, et al.
Molecular Genetics and Metabolism Reports|November 9, 2020
Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotypeRobert J Hopkin, Ulla Feldt-Rasmussen, Dominique P Germain, et al.
American Journal of Medical Genetics. Part A|March 29, 2019
Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT studyDerralynn A Hughes, Kathleen Nicholls, Gere Sunder-Plassmann, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Plos One|November 15, 2023
Transcultural adaptation and validation of the Serbian version of Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-Patient Satisfaction (FACIT-TS-PS) questionnaireIvana Radovic, Igor Krdzic, Ana Jovanovic, et al.
Molecular Genetics and Metabolism Reports|July 24, 2025
Iron metabolism and hematological abnormalities in adult patients affected with mucopolysaccharidosesGabija Kaciulyte, Goknur Yorulmaz, Reena Sharma, et al.
JIMD Reports|December 8, 2017
Haematopoietic Stem Cell Transplantation Arrests the Progression of Neurodegenerative Disease in Late-Onset Tay-Sachs DiseaseKarolina M Stepien, Su Han Lum, J Edmond Wraith, et al.
Nanoscale|May 11, 2023
Defect-free graphene enhances enzyme delivery to fibroblasts derived from patients with lysosomal storage disordersYingxian Chen, Tooba Taufiq, Niting Zeng, et al.
Orphanet Journal of Rare Diseases|January 7, 2022
Cardiac device implantation and device usage in Fabry and hypertrophic cardiomyopathyRavi Vijapurapu, William Bradlow, Francisco Leyva, et al.
JIMD Reports|May 17, 2017
Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry RegistryWilliam R Wilcox, Ulla Feldt-Rasmussen, Ana Maria Martins, et al.
Frontiers in Cardiovascular Medicine|December 25, 2023
Clinical utilisation of implantable loop recorders in adults with Fabry disease-a multi-centre snapshot studyAshwin Roy, Ravi Vijapurapu, Hibba Kurdi, et al.
Orphanet Journal of Rare Diseases|October 21, 2023
Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label studyAleš Linhart, Gabriela Dostálová, Kathy Nicholls, et al.
Molecular Genetics and Metabolism Reports|November 9, 2020
Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotypeRobert J Hopkin, Ulla Feldt-Rasmussen, Dominique P Germain, et al.
American Journal of Medical Genetics. Part A|March 29, 2019
Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT studyDerralynn A Hughes, Kathleen Nicholls, Gere Sunder-Plassmann, et al.
Pageof 6